Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection

April 18, 2025 updated by: Yuxi Zhang, Lanzhou University Second Hospital
The aim of this study is to compare the diagnostic efficacy of 68Ga-CTR-FAPI PET/CT and 18F-FDG PET/CT in various malignant tumors

Study Overview

Status

Completed

Conditions

Detailed Description

This study recruited malignant tumor patients diagnosed by histopathology and imaging at the Nuclear Medicine Department of Lanzhou University Second Hospital from July 2024 to March 2025. The enrolled patients underwent 68Ga-CTR-FAPI PET/CT and 18F-FDG PET/CT scans within one week.

Study Type

Observational

Enrollment (Actual)

27

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Gansu
      • Lanzhou, Gansu, China, 730030
        • The Second Hospital of Lanzhou University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Malignant tumor patients diagnosed by histopathology and imaging

Description

Inclusion Criteria:

(a) Age ≥ 18 years old; (b) Suspected or newly diagnosed malignant tumors, evaluating the therapeutic effect of the tumor, or discovering recurrence/metastasis; (c) Obtain approval from oncologists and agree to undergo 18F-FDG and 68Ga-CTR-FAPI PET/CT scans within one week.

Exclusion Criteria:

(a) Pregnancy or lactation period; (b) Claustrophobia. (c) Serious health problems: such as severe heart, liver and kidney dysfunction, diseases that affect the metabolism or clearance of imaging agents.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lesion uptake
Time Frame: 1 day
Standardized uptake value (SUV)
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Lanzhou University Second Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2024

Primary Completion (Actual)

March 31, 2025

Study Completion (Actual)

April 5, 2025

Study Registration Dates

First Submitted

April 18, 2025

First Submitted That Met QC Criteria

April 18, 2025

First Posted (Actual)

April 25, 2025

Study Record Updates

Last Update Posted (Actual)

April 25, 2025

Last Update Submitted That Met QC Criteria

April 18, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • YZhang

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe